Engflag

Urocare

Quick links to important sections

Urocare

Urocare_EN

Method of action: Antibacterial Broad Spectrum (Bactericidal), Bactericidal

Treatment option: Infection, Infection,Urinary Tract, Acute Bacterial Cystitis, Fits, Infection Prophylaxis, Urethritis, Cystitis

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Urocare

What is Urocare? (Fosfomycin)

Property Description
Active Ingredient Fosfomycin (as tromethamine salt)
Form Granule for oral solution (Single-dose sachet)
Pharmacological Class Broad-spectrum Antibiotic (Miscellaneous)
General Purpose Bacterial elimination/Anti-infective action
Origin Synthetic

Urocare: Definition and Pharmacological Type

Urocare is a synthetic anti-infective medicine based on the active ingredient Fosfomycin, most commonly utilized as the salt Fosfomycin tromethamine. It is formally classified as a broad-spectrum antibiotic belonging to the miscellaneous group of antibacterials (ATC J01XX01), a classification based on its unique chemical structure. This classification is significant as it sets Fosfomycin apart from conventional antibiotic families, such as penicillins and cephalosporins, minimizing potential cross-resistance issues. It is typically available by prescription only (Rx), underscoring its role in targeted antimicrobial therapy.

Composition, Origin, and Form

The Urocare product is a single active ingredient preparation that comes as a granule for oral solution, which is a powder packaged in a sachet intended to be dissolved in water for oral administration. The use of the tromethamine salt is essential to its formulation, as this salt form significantly enhances the oral absorption of the active Fosfomycin molecule. This specific oral dosage form simplifies the initiation of therapy, making it a distinctive option for patients needing a potent anti-infective.

General Purpose and Bactericidal Action

The general purpose of Urocare is to swiftly and effectively eliminate susceptible bacterial pathogens that cause infection. This function is achieved through its bactericidal action, confirming that it actively kills the targeted microorganisms rather than simply inhibiting their growth. The fundamental mechanism involves the drug disrupting the earliest stages of bacterial cell wall synthesis. This unique action delivers the core benefit of effective pathogen clearance, regardless of the bacterial resistance status against older antibiotic classes.

Regulatory References

  1. FDA label for MONUROL (Fosfomycin tromethamine)

What side effects are possible with Urocare?

Possible Side Effects and Safety Information

The safety profile for Urocare (Fosfomycin tromethamine) is formally documented in government regulatory materials, classifying possible adverse reactions by frequency and affected body system. The adverse effects profile is primarily characterized by reactions within the gastrointestinal and nervous systems.

Frequency-Classified Adverse Reactions

The following are classified according to official frequency standards:

Classification Examples of Reactions
Common Diarrhea, Nausea, Headache
Uncommon Dizziness, Abdominal pain, Dyspepsia, Vulvovaginitis, Fatigue
Rare Optic neuritis

Serious adverse reactions, though of unknown frequency, are explicitly noted in labeling. These include severe anaphylactic reactions (including shock), angioedema (swelling beneath the skin), and Pseudomembranous colitis (a severe form of antibiotic-associated diarrhea).

Safety Constraints and Special Populations

Official documents define specific safety limitations and population-based notes:

  • Contraindication: The medicine is contraindicated in individuals with known hypersensitivity to Fosfomycin.
  • Drug Interaction Safety: Co-administration with Metoclopramide is noted to potentially lower serum Fosfomycin concentrations and should be avoided.
  • Pregnancy and Lactation: Use during pregnancy is advised only if clearly necessary. Low concentrations of the active ingredient are known to be excreted in human milk.
  • Pediatrics (le 12 years): The safety and effectiveness of the oral granule formulation have not been established in pediatric patients 12 years of age and younger.

This regulatory mapping establishes the structured risk characteristics, ranging from common, less severe effects to rare but serious systemic reactions.

Overdose and Emergency Response

In the event of a suspected overdosage with Urocare, government regulatory guidance mandates that a patient seek emergency medical attention immediately or contact a Poison Control Centre. This action is required even if initial symptoms are not yet apparent.

Documented Manifestations

Official regulatory labeling describes several documented manifestations of toxicity following high exposure. These include specific sensory and neurological signs such as impaired hearing, vestibular loss (loss of balance function), and alterations in taste perception, including a metallic taste.

Severe Outcomes and Monitoring Requirements

In cases associated with high systemic exposure, severe systemic findings have been documented, including somnolence, hypotonia, and serious electrolyte disturbances (such as hypernatremia or hypokalemia). Regulatory requirements mandate that the patient be monitored in a clinical setting, specifically for plasma/serum electrolyte levels.

Management and Clearance

Treatment for an overdose is mandated to be exclusively symptomatic and supportive. Regulatory information states that no specific antidote is known. To assist in the clearance of the active substance, rehydration is recommended to promote urinary elimination. Furthermore, the official prescribing information notes that the substance is effectively cleared by haemodialysis in situations of severe exposure. This approach defines the required clinical response to an overdose situation.

Therapeutic Uses of Urocare

Urocare (Fosfomycin) is prescribed as an anti-infective agent considered relevant for specific bacterial infections localized to the lower urinary tract. The oral granule formulation is indicated only for the treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis.

Treating Acute, Uncomplicated Bladder Infections

The medication is commonly used in clinical settings to treat acute cystitis, a condition presenting with acute or disruptive episodes. Its central therapeutic benefit is the management of susceptible bacterial pathogens, applied to help address the underlying infection and support the management of acute symptom patterns.

Alleviating Distressing Urinary Symptoms

Urocare may be part of the symptomatic management of the characteristic symptom cluster. This helps ease symptoms related to physical discomfort like pain or burning upon urination (dysuria) and is relevant for easing symptoms related to heightened physiological activity (frequent, urgent need to pass urine). The medication may assist with symptomatic relief that contributes to easing day-to-day comfort during the acute episode.

Quick Fact: Relief for Urinary Discomfort

The medication is commonly used for managing symptoms that interfere with daily functioning, providing supportive relief when symptoms become more noticeable and contributes to easing the overall symptom load during acute lower urinary tract infections.

Regulatory References

  1. U.S. FDA Drug Label for Fosfomycin

Eligibility and Restrictions for Use

Who Can and Cannot Use Urocare?

This section outlines the official population eligibility for Urocare (Fosfomycin tromethamine oral granules) as defined by global regulatory bodies.

Populations Generally Eligible

Urocare is approved for use primarily in adult women (or female adolescents in some regions) diagnosed with uncomplicated acute cystitis (lower urinary tract infection). Dosage adjustment is typically not required for older adult patients or those with mild to moderate kidney function impairment.

Absolute Contraindications

The medicine is contraindicated and must not be used by patients with a history of hypersensitivity (severe allergy) to fosfomycin or any excipients. It is also prohibited for individuals with severe renal impairment (Creatinine Clearance < 10 mL/min). The drug is not indicated for serious conditions like pyelonephritis (kidney infection) or abscess.

Use Restrictions and Limitations

Safety and effectiveness have not been established in children aged 12 years and under. For pregnant or breastfeeding individuals, use is subject to conditional approval and is recommended only if determined to be clearly necessary by a healthcare professional.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation confirms that Urocare (Fosfomycin) is subject to pharmacokinetic interactions that affect its absorption and excretion. The primary interaction types involve substances that alter gastrointestinal motility and those that interfere with renal clearance, resulting in modification of the drug's overall exposure.

Documented Pharmacokinetic Interactions

Interacting Substance Official Interaction Outcome (Type) Restriction/Requirement
Metoclopramide Lowers serum concentrations and decreases urinary excretion of fosfomycin. Not formally contraindicated, but co-administration reduces drug exposure.
Probenecid Decreases the renal clearance and excretion of fosfomycin. Results in higher serum levels due to renal tubular blocking.
Cimetidine Does not significantly affect the pharmacokinetics or urinary concentrations. No interaction of clinical significance is documented.

Food and Timing Requirements

Co-administration with a high-fat meal reduces the oral bioavailability and delays the time taken to reach peak plasma levels. This effect on absorption necessitates a timing-based interaction rule: the medication is officially recommended to be taken on an empty stomach or at least two to three hours after a meal to achieve optimal peak concentrations. No specific warnings or restrictions for interactions with alcohol, herbal products, or common supplements are consistently documented across major regulatory labels.

Furthermore, regulatory information notes that the drug's half-life and urinary recovery are impacted by renal impairment, a population-specific factor that significantly decreases the medicine’s clearance.

Mechanism of Action

Urocare’s mechanism begins with its active uptake into the bacterial cytoplasm, primarily utilizing the GlpT and UhpT transport systems. Once inside, the molecule functions as an irreversible inhibitor of the key bacterial enzyme, UDP-N-acetylglucosamine enolpyruvyl transferase (MurA). By forming a permanent covalent bond with a specific residue on MurA, the drug immediately halts the enzyme's function, preventing the production of foundational peptidoglycan precursors required for the bacterial cell wall. The downstream physiological consequence of inhibiting MurA is the failure of the bacteria to assemble a stable cell wall structure. This structural deficiency renders the microorganism unable to withstand its own internal osmotic pressure. The subsequent rupture (lysis) of the cell is the result of this cascade, achieving a bactericidal effect that targets a fundamental process unique to the pathogen. The mechanism is entirely reliant on the functional integrity of the bacterial transport proteins for drug entry. Any genetic mutation or downregulation of the GlpT or UhpT transporters limits the drug's access to its cytoplasmic target, thereby acting as a primary biological constraint that limits the drug's ability to inhibit the MurA enzyme.

Dosage and Administration Information

How to Use Urocare: Administration Guidelines

Urocare (Fosfomycin tromethamine) is administered based on a standardized, single-dose regimen that structures the entire course of therapy as a singular event. The instructions define the precise method, dose, and preparation requirements.

Administration Scope and Dosage

Instruction Detail
Route of Administration Oral administration only, after dissolution.
Dosing Schedule A single dose of 3 g of fosfomycin. This constitutes the entire course of treatment.
Frequency Pattern Single-dose (one time administration only) for the approved indication.
Timing in Relation to Meals Can be taken without regard to meals (with or without food).

Preparation and Procedural Requirements

The full 3 g dose is delivered via a preparation step that ensures the active ingredient is correctly constituted for ingestion. The granules must not be administered in their dry form.

Preparation Sequence:

  • The entire contents of the sachet must be emptied into a glass.
  • Approximately 3 to 4 ounces (about 1/2 cup) of cold water should be poured into the glass (hot water is not to be used).
  • The mixture must be stirred until the granules are completely dissolved.
  • The resulting solution must be consumed immediately after preparation, and no part of the prepared mixture should be saved for later use.

Age-Group Rules

Urocare is approved for use in women age 18 years and older. Standard guidelines for the single-dose oral product do not specify dosage adjustments for older adults or for patients with impaired kidney function, although the drug's elimination half-life is known to be prolonged in the setting of reduced renal function.

Recent Clinical Evidence

Urocare: Recent Clinical Evidence

This section summarizes key research findings related to Urocare's evaluation in clinical settings. The data below is descriptive and intended for informational purposes only.

I. Phase III Clinical Trials

The initial development of the drug was based on laboratory studies. The primary goal of the main Phase III trial was designed to examine changes in measured pain and inflammation markers among adults.

  • Primary Findings: The drug was evaluated in studies exploring its potential to modify the course of the condition. Studies assessed symptom change over the short- and long-term.
  • Population Studied: The trial included 1,250 adult participants diagnosed with severe, refractory inflammation. The mean duration of follow-up was 48 weeks.
  • Secondary Outcomes: The Phase III study also evaluated whether it impacted quality of life and the frequency of flare-ups reported by participants.

II. Safety Profile and Risk Management

The safety profile was assessed in clinical trial settings, and the most frequently reported adverse events included gastrointestinal issues, fatigue, and headache.

  • Serious Adverse Events: A small percentage of participants (1.2%) experienced serious adverse events, including three cases of liver enzyme elevation and two cases of acute kidney injury.
  • Monitoring: Liver enzyme and kidney function measurements were closely tracked for participants during the initial weeks of the trials.
  • Risk Mitigation: Safety studies tracked the frequency and severity of side effects in comparison to placebo.

III. Combination Therapy Research

While the main trials focused on monotherapy, research has explored the potential of combining the two approaches (Urocare and an established therapy) in a small Phase II study involving 150 patients. Information remains limited regarding the long-term findings from the combination study. Further research is required to clarify the potential role of combined treatment.

Key Studies & References

  1. Assessment of Combination Therapy Safety and Pharmacokinetics in Urological Disease: A Phase 2 Open-Label Study
  2. Real-world Safety Profiles of Biological Therapies in Inflammatory Bowel Disease (IBD): A Post-marketing Pharmacovigilance Observational Study

How should Urocare be stored and disposed of?

How to Store and Dispose of Urocare? (Fosfomycin Granules)

The storage and disposal of Urocare (Fosfomycin tromethamine granules) must strictly follow official regulatory guidelines to maintain product stability and ensure environmental protection.

Storage Conditions

Requirement Official Instruction
Temperature Store at controlled room temperature (20 C to 25 C), with brief excursions up to 30 C.
Protection Keep in the original container (sachet) and protect from moisture.
Stability The solution must be administered immediately after mixing; do not store the reconstituted liquid.
Child Safety Must be stored out of the sight and reach of children.

Disposal Instructions

Any unused or expired Urocare product must be discarded in accordance with local requirements for pharmaceutical waste. The official labeling specifies that the medicine must not be disposed of via wastewater or routine household garbage to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagTurkey

Equivalent of Urocare found in:

A-Z Index: